Renalytix AI Announces Fundraising, Executive Changes, and Shareholder Approval
Company Announcements

Renalytix AI Announces Fundraising, Executive Changes, and Shareholder Approval

Renalytix AI (RNLX) just unveiled an update.

Renalytix plc successfully raised approximately $0.5 million in a registered direct offering by selling over 2.6 million shares, with an option for the buyer to purchase additional shares later extended. Amidst these developments, Thomas McLain announced his resignation as President, effective at the end of April, with Howard Doran set to take over the role. Meanwhile, the company’s general meeting saw shareholders approve proposals related to the allotment and issue of shares, with a significant majority voting in favor, showcasing investor confidence and compliance with regulatory requirements.

See more insights into RNLX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyThree new option listings and two option delistings on October 8th
TheFlyRenalytix commences trading on OTCQB in U.S.
TheFlyRenalytix announces collaboration with Steno Diabetes Center
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App